Evaluation of the expression of the stromal cell-derived factor-1 alpha (CXCL 12) in psoriatic patients after treatment with Methotrexate.

Nagwa H AbdelaalNadia G ElhefnawyShymaa R AbdulmonemSafenaz SayedNoha A SalehMarwah Adly Saleh

Published in: Journal of cosmetic dermatology (2019)

CXCL12 might be involved in the progression of psoriasis vulgaris to PsA. MTX therapy downregulated the expression of CXCL12 of the keratinocytes of psoriasis patients. This downregulation was paralleled by decrease in the PASI score. CXCL12 can be used as a biological marker of disease severity of psoriasis patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
prostate cancer
poor prognosis
prognostic factors
peritoneal dialysis
stem cells
low dose
bone marrow
atopic dermatitis
cell therapy